In this regard, we do recognize that the main weakness of our study is the lack of experimental evidence supporting the antitumor activity of IL-8- or CXCR1/2-neutralizing antibodies in cultured and xenografted HRG-overexpressing/ER+ breast cancer cells. This evidence concerns the gene CXCR1 and breast carcinoma.